Abstract
Background Treatment-Resistant Depression (TRD) refers to patients with major depressive disorder who do not remit after two or more antidepressant trials. TRD is common and highly debilitating, but its neurobiological basis remains poorly understood. Recent neuroimaging studies have revealed cortical connectivity gradients that dissociate primary sensorimotor areas from higher-order associative cortices. This fundamental topography determines cortical information flow and is affected by psychiatric disorders. We examined how TRD impacts this hierarchical cortical organization.
Methods We analyzed resting-state fMRI data from a mindfulness-based intervention study in 56 TRD patients and 28 healthy controls. Using novel gradient extraction tools, measures of cortical gradient dispersion within and between functional brain networks were derived, compared across groups, and associated with graph theoretical measures of network topology. Within TRD, baseline cortical gradient dispersion measures were correlated with baseline clinical measures (anxiety, depression, mindfulness), as well as with changes in these measures following treatment with either mindfulness-based therapy or a health enhancement program.
Results Cortical gradient dispersion was reduced within major intrinsic brain networks in TRD. Reduced cortical gradient dispersion correlated with increased network modularity assessed through graph theory-based measures of network topology. Lower dispersion among Default Mode Network regions, a transmodal system linked to depression symptomatology, related to current levels of trait anxiety, depression, and mindfulness, but not to changes in these domains following treatment.
Conclusions Our findings reveal widespread alterations in cortical gradient architecture in TRD, implicating a significant role for the Default Mode Network in mediating depression, anxiety, and lower mindfulness in patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT00871299
Funding Statement
This work was supported by NIH grant K99-AG065457 to LP, DP2-MH119735 to MS, NIH/NCCAM grant R01-AT004572-02S1 to SJE and DHM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants or their surrogates provided written informed consent prior to participation in accordance with the declaration of Helsinki. The University of California San Francisco Committee on Human Research approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Participants data is not publicly shared due to privacy concerns but is available from the corresponding author after reasonable request.
